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TIMING OF 1ST RECURRENCE AFFECTS SUBSEQUENT CLINICAL
OUTCOME IN 1ST RECURRENT LOW GRADE TA BLADDER CANCER
Hiroaki Kobayashi 1, Eiji Kikuchi 1, Takahiro Maeda 2, Nobuyuki
Tanaka 1, Kazuhiro Matsumoto 1, Akira Miyajima 1, So
Nakamura 2, Mototsugu Oya 1. 1Department of Urology, Keio University
School of Medicine, Japan; 2Department of Urology, Tokyo Saiseikai Central
Hospital, Japan
Purpose: Recurrent non-muscle invasive bladder cancer (NMIBC) is very
heterogeneous population due to the variability of recurrent timing, fre-
quency of recurrence, and prior adjuvant therapy performed or not. There
were no studies focusing on 1st recurrent low grade Ta tumor to evaluate
the efﬁcacy of adjuvant intravesical therapy or the timing of 1st rec. for
subsequent outcomes.
Materials and Methods: Among 814 cases with an initial diagnosis of
NMIBC, 139 cases with 1st recurrent TaG1/2 tumor without BCG therapy
were included in this study. We divided the patients into 4 groups ac-
cording to the timing of 1st rec. (Period 1; < 3M, also deﬁned as “early 1st
rec.”, Period 2; 3-12M, Period 3; 12-24M, Period 4; >24M) and evaluated
whether the timing of 1st rec. or the adjuvant intravesical therapies for 1st
rec. could affect the subsequent tumor recurrence (2nd rec.). The starting
point of this study was the day of the 1st rec. and the median follow-up
was 58.9 months.
Results: After the 1st rec., BCG and MMC instillation were performed in 69
and 16 patients. Second rec. occurred in 56 patients and consisted of TaG1/
2 tumor in 40 patients (71.4%). At initial diagnosis, 110 of 139 patients
(79.1%) were TaG1-2 tumor and 31 of the 56 patients with 2nd rec. (55.4%)
presented TaG1-2 form three times in a row. The 3- and 5-year 2nd rec. free
survival rates were not signiﬁcantly different among the patients treated
with (a) BCG (68.5%, 60.4%, respectively), (b) MMC (81.3%, 67.7%, respec-
tively), and (c) no therapy (56.4%, 42.4%, respectively) ((a) vs (c); p¼ 0.226,
(b) vs (c); p ¼ 0.114). In each timing of the 1st rec., no signiﬁcant difference
on 2nd rec. rate was observed between BCG group and no therapy groups.
The 3-year 2nd rec.-free survival rates in patients of early 1st rec. was 33.3%,
which was signiﬁcantly lower than those who recurred after 3 months
(combined Period 2 to 4, 67.7%). Multivariate analysis demonstrated that
early 1st rec. was the only independent predictor for 2nd rec.
Conclusion: Most of the 1st recurrent low grade Ta tumors had a history of
and recurred as low grade Ta form. Early 1st rec. was the independent
predictor for 2nd rec. whereas adjuvant therapy after 1st rec. did not reduce
2nd rec. regardless of the timing of 1st rec.
IPD08:
ASSOCIATION OF HEPATITIS AND RENAL CELL CARCINOMA: RESULTS
FOR LONGITUDINAL NATIONAL HEALTH INSURANCE DATABASE IN
TAIWAN
Tzu-Hsiang Wu1, Yi-Chia Lin 1,2, Chi-Hui Bai 3, Ji-Fan Lin 4, Te-Fu
Tsai 1,2, Hung-En Chen 1, Kuang-Yu Chou 1,2, Thomas I-Sheng
Hwang 1,2. 1Division of Urology, Department of Surgery, Shin Kong Wu
Ho-Su Memorial Hospital, Taiwan; 2 School of Medicine, Fu-Jen Catholic
University, Taiwan; 3 School of Public Health, Taipei Medical University,
Taiwan; 4Central Laboratory, Shin Kong Wu Ho-Su Memorial Hospital,
Taiwan
Purpose: Several cancers were identiﬁed to be related to viral infection
such as cervical cancer and human papilloma virus, and hepatocellular
carcinoma (HCC) and hepatitis virus etc. A clinical observation of the
relationship between hepatitis virus and renal cell carcinoma (RCC) was
reported. We conduct a study using national health insurance database
to see if the relationship of hepatitis virus and renal cell carcinoma.
Materials and Methods: A population based cohort study was conducted
using Taiwan national health insurance database. A million patients were
randomly selected from the longitudinal health insurance database 2005.
Birth after January 1st, 2004 were excluded. The remaining 964846 pa-
tients were identiﬁed. Patients with a history of end-stage renal disease,
hepatocellular carcinoma and renal cell carcinoma were also excluded.
Results: A total of 956679 patients were enrolled. Among them, 19533 pa-
tientswere identiﬁed to have B or C hepatitis infection (either in the status ofactive infection or carrier) and 937146 were non-hepatitis patients. The
incidence of new onset ESRD, newly diagnosed HCC, and newly-diagnosed
RCCweresigniﬁcantlyhigher inhepatitispatients (1.09%vs.1.83%,p < 0.001;
4.17% vs. 0.17%, p < 0.001; and 0.11% vs. 0.06%, p ¼ 0.0066, respectively).
Univariate andmultivariate hazard ratioof RCC inpatientswithhepatitiswas
3.318, 95% CI: 2.16 e 5.09 and 2.578, 95% CI: 1.68 e 3.96, respectively.
Conclusions: B or C hepatitis infection is associated with increased risk of
RCC from the longitudinal national health database analysis.
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TREATMENT-RELATED DETERIORATION OF RENAL FUNCTION AS A
BIOMARKER TO PREDICT ANTI-TUMOR EFFICACY OF SUNITINIB IN
PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Hironori Fukuda, Tsunenori Kondo, Yasunobu Hashimoto, Hirohito
Kobayashi, Jumpei Iizuka, Toshio Takagi, Kazunari Tanabe. Department of
Urology, Tokyo Women's Medical University, Japan
Purpose: To investigate the relationship between treatment-related
deterioration of renal function and anti-tumor efﬁcacy in metastatic renal
cell carcinoma (mRCC) patients treated with sunitinib.
Materials and Methods: We retrospectively reviewed the medical records
of mRCC patients whowere treated with sunitinib for more than 3months.
Patients receiving hemodialysis before receiving sunitinib as well as those
who did not undergo nephrectomy were excluded from our analysis. Renal
function was evaluated by the estimated glomerular ﬁltration rate (eGFR)
calculated using the MDRD equation modiﬁed for Japanese patients. The
degree of deterioration in eGFR was compared with progression-free
survival (PFS).
Results: Sixty-two patients were enrolled, the median age was 65 years,
and 44 patients (71%) were male. The median baseline eGFR was 49.1 ml/
min/1.73 m2, and median decrease of eGFR was 9.9 ml/min/1.73 m2. Forty-
seven patients (76%) had a decreased eGFR of more than 10% compared to
baseline values. The patients showing this decrease had signiﬁcantly
longer PFS than those who did not (PFS: 15.5 months vs. 6.1 months,
respectively; P ¼ 0.001). On multivariate analysis, a decrease in eGFR of
more than 10% was a signiﬁcant, independent factor for predicting longer
PFS (hazard ratio, 0.37; 95% conﬁdence interval, 0.17-0.83; P ¼ 0.017) as
well as MSKCC risk groups and the number of sunitinib treatment cycles.
Conclusion: Treatment-related deterioration of renal function may be a
biomarker to predict better treatment efﬁcacy for use of sunitinib in pa-
tients with mRCC.ISTUA Podium-2
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ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY FOR HILAR AND NON-
HILAR TUMORS: PERIOPERATIVE OUCTOMES
Shih-Yen Lu 1, Hsiao-Jen Chung 1,2, Yi-Hsiu Huang 1,2, Tzu-Ping Lin 1,2, Alex
T.L. Lin 1,2, Kuang-Kuo Chen 1,2. 1Department of Urology, Taipei Veterans
General Hospital, Taiwan; 2Department of Urology, School of Medicine,
National Yang-Ming University, Taipei, Taiwan
Purpose: The aim of this study was to compare the perioperative outcome
between hilar tumors and non-hilar tumors after robotic-assisted partial
nephrectomy (RAPN).
Materials and Methods: A retrospective review of 160 patients who un-
derwent RAPN for a solitary renal tumor fromDecember 2009 to September
2014 at our institution was performed. A total 163 tumors received
consecutive RAPN were recruited. Demographic data and perioperative
outcomeswere compared between the hilar tumor group (n¼ 25) and non-
hilar tumor group (n ¼ 137). One hilar tumor case was converted to open
method due to grossly vessel invasion and was excluded for analysis.
Results: In demographic data, there was no difference between age,
gender and American Society of Anethesiologists (ASA) physical status
score. Hilar tumor group had less BMI (23.5 vs 25.4, p ¼ 0.022) and had
larger preoperativemaximal tumor size (4.9cmvs 3.6 cm, p < 0.001). Hilar
tumor group had higher PADUA score (10.7 vs 8.4, p < 0.001) and higher
